

**RatnerPrestia**

WE SPECIALIZE IN THE LAW OF CREATIVITY®

**RECEIVED  
CENTRAL FAX CENTER****MAR 13 2007**

☐  
Suite 301, One Westlakes, Berwyn  
P.O. Box 980  
Valley Forge, PA 19482-0980  
Phone: 610-407-0700  
Fax: 610-407-0701

☒  
Nemours Building  
1007 Orange Street, Suite 1100  
P.O. Box 1596  
Wilmington, DE 19899  
Phone: 302-778-2500  
Fax: 302-778-2600  
[www.ratnerprestia.com](http://www.ratnerprestia.com)

☐  
Suite 265  
Commerce Corporate Center  
5100 Tilghman Street  
Allentown, PA 18104  
Phone: 610-530-8100  
Fax: 610-530-8200

**FAX FILING IN U.S. PATENT & TRADEMARK OFFICE**DATE: March 13, 2007

TIME: \_\_\_\_\_

TO: Mail Stop: Amendment, Commissioner of Patents and Trademarks		FAX NO.: (571)273-8300
FROM: Frank P. Tise, Reg. No. 50,379	ADMIN. ASST.: Gayle D. Bay	
APPLN. NO.: 10/521,994	ATTY. DOCKET NO.: RCHP-132US	
TITLE OF APPLN.: STEROID LIPID-MODIFIED POLYURETHANE AS AN IMPLANTABLE BIOMATERIAL, THE PREPARATION AND USES THEREOF		
FILING DATE: January 19, 2005	ART UNIT: 1711	EXAMINER: Benjamin Gillespie
FIRST INVENTOR: Robert J. Levy et al.	CONF. NO.: 1713	
LIST OF ATTACHMENTS: Transmittal (1 p); Preliminary Amendment (8 pp).		

Total Number of Pages: 10 (including this form)**COMMENTS**

Thank you.

**CONFIDENTIAL AND PRIVILEGED ATTORNEY/CLIENT INFORMATION**

This facsimile transmission (and/or documents accompanying it) may contain attorney/client privileged communications and confidential business information that is intended for use only by the individual or company to whom it is addressed. Disclosure, interception, copying or any other use of this transmission by anyone other than any intended recipient is prohibited. If you receive this transmission by mistake, please notify the sender.

***Please notify us immediately if you have not received the number of pages indicated above.***

MAR 13 2007

PTO/SB/21 (09-04) (AW 10/2004)


Approved for use through 7/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/521,994
	Filing Date	January 19, 2005
	First Named Inventor	Robert J. Levy et al.
	Art Unit	1711
	Examiner Name	Benjamin Gillespie
Total Number of Pages in This Submission	Attorney Docket No.	RCHP-132US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/Declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Fax Cover Sheet
Remarks:		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT			
Firm Name	RatnerPrestia		
Signature			
Printed Name	Frank P. Tise		
Date	March 13, 2007	Registration No.	50,379

CERTIFICATE OF TRANSMISSION / MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or Printed Name	Gayle D. Bay	Date	March 13, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, ALEXANDRIA, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**RECEIVED  
CENTRAL FAX CENTER**

MAR 13 2007

RCHP-132US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appln. No: 10/521,994  
Applicant: Robert J. Levy et al.  
Filed: January 19, 2005  
Title: STEROID LIPID-MODIFIED POLYURETHANE AS AN IMPLANTABLE  
BIOMATERIAL, THE PREPARATION AND USES THEREOF  
TC/A.U.: 1711  
Examiner: Benjamin Gillespie  
Confirmation No.: 1713  
Docket No.: RCHP-132US

**PRELIMINARY AMENDMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Prior to examination, please amend the above-identified application as follows:

- ☐ **Amendments to the Specification** begin on page \_\_\_\_\_ of this paper.
- ☒ **Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.
- ☐ **Amendments to the Drawings** begin on page \_\_\_\_\_ of this paper and include an attached replacement sheet(s).
- ☐ **Amendments to the Abstract** are on page \_\_\_\_\_ of this paper. A clean version of the Abstract is on page \_\_\_\_\_ of this paper.
- ☒ **Remarks/Arguments** begin on page 8 of this paper.